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Glycosylation produces an abundant, diverse, and highly regulated repertoire of cellular 
glycans that are frequently attached to proteins and lipids. The past decade of research on 
glycan function has revealed that the enzymes responsible for glycosylation—the glycosyl-
transferases and glycosidases—are essential in the development and physiology of living 
organisms. Glycans participate in many key biological processes including cell adhesion, 
molecular trafficking and clearance, receptor activation, signal transduction, and endocytosis. 
This review discusses the increasingly sophisticated molecular mechanisms being discov-
ered by which mammalian glycosylation governs physiology and contributes to disease.Glycans are one of the four basic components of cells 
and may also be the most abundant and diverse of 
nature’s biopolymers. Existing as covalent linkages of 
saccharides often attached to proteins and lipids, gly-
cans constitute a significant amount of the mass and 
structural variation in biological systems. The field of 
glycobiology is focused upon understanding the struc-
ture, chemistry, biosynthesis, and biological function of 
glycans and their derivatives. Glycobiology has a long 
history that began with investigations of the basic con-
stituents of cells and the nature of the polysaccharide 
carbohydrate component. Clinical applicability arose 
early with the discovery of the human blood groups, 
although evidence that these were glycan antigens 
came later (Landsteiner, 1931). In addition, the anti-
thrombotic glycan heparin is one of the most commonly 
used drugs (Linhardt, 1991; Shriver et al., 2004), with 
current estimates of a billion doses prescribed annu-
ally. As glycobiology is increasingly interrelated with 
other disciplines, nomenclature and terminology within 
the field continue to evolve. The word glycan is now 
often used to encompass oligosaccharide, polysac-
charide, and carbohydrate, as not all glycans are oligo-
mers and the term carbohydrate can be confused with 
components of intermediary energy metabolism. More 
recently, in parallel with approaches to define genom-
ics, proteomics, and lipidomics, the term “glycomics” 
has emerged, which refers to the study of the glycan 
structures that compose an organism’s “glycome.”
The mammalian glycome repertoire is estimated to be 
between hundreds and thousands of glycan structures, 
and could be larger than the proteome. Although the 
diversity of glycan structures theoretically is vast, con-
straints are provided by the mechanisms of glycan syn-
thesis and regulation. Mammalian glycans are formed 
by an endogenous portfolio of cellular enzymes and substrates that have been retained in an evolutionary 
investment encompassing millions of years and span-
ning 1%–2% of the genome. Vertebrates, and especially 
mammals, have evolved a highly complex glycan reper-
toire that is structurally distinct from that of invertebrates, 
lower eukaryotes, and prokaryotes. It is increasingly evi-
dent that the variation in glycomes among organisms is 
a molecular basis for interspecies recognition systems. 
Glycans of nonvertebrate organisms, for example, can 
modulate the development and activation of the mamma-
lian immune system (Cobb and Kasper, 2005). Mamma-
lian glycans are remarkably well conserved, but species-
specific variations also exist, and these differences may 
be involved in the emergence of distinct traits including 
susceptibilities to infectious pathogens (Gagneux and 
Varki, 1999; also see the Essay by A. Varki, page 841 of 
this issue). Engineering new chemical modifications into 
glycans of living cells may improve the ability to detect 
glycan function and contribute to future diagnosis and 
treatment of disease (Prescher et al., 2004; also see the 
Minireview by J. Prescher and C. Bertozzi, page 851 of 
this issue). Indeed, glycosylation defects in mice as well 
as humans and their links to disease have shown that 
the mammalian glycome contains a significant amount 
of biological information (Lowe and Marth, 2003; Freeze, 
2006). This review focuses upon the involvement of 
mammalian glycans in the molecular and cellular mech-
anisms that control health and disease.
Structure and Topology of Mammalian Glycosylation
Nine monosaccharides are used in the enzymatic pro-
cess of glycosylation in mammals. Conserved biosyn-
thetic pathways provide all nine monosaccharides from 
sugars and precursors ubiquitously present in the diet. 
Except in cases of rare genetic defects, dietary intake of 
monosaccharides or mammalian glycans has not been Cell 126, September 8, 2006 ©2006 Elsevier Inc. 855
Figure 1. Mammalian Glycan Linkages 
Produced by Glycosylation
There are nine nucleotide sugar donors and mul-
tiple protein and lipid acceptor motifs for glycosyl-
transferases, which produce 14 different glycans in 
stereoisomeric configurations (α or β) linked at the 
number 1 position of the donor sugar ring. The at-
tached monosaccharide frequently then becomes 
a saccharide acceptor in 1 of 49 other glycosyl-
transferase reactions. This results in glycosidic 
bonds with α or β configurations of the donor sac-
charide linked through position 1 or 2 to position 
2, 3, 4, or 6 of an acceptor saccharide. Glycan 
diversification is dictated by the combinatorial and 
regulated application of this enzymatic potential. 
This includes hyaluronan synthesis, which oc-
curs by copolymerization of two nucleotide sugar 
donors. The formation of iduronic acid by the 
epimerization of glucuronic acid subsequent to 
glycosylation is not depicted. Although some di-
saccharide sequences are found on multiple types 
of glycans, others are specific to one or few glycan 
types. Those potential mammalian disaccharide 
sequences that have not been observed in nature 
are indicated (−). N-glycosylation (*) is initiated by 
transfer en bloc of a presynthesized dolichol lipid-
linked oligosaccharide precursor. Ser/Thr, serine/
threonine; Asn, asparagine; hLys, hydroxylysine; 
Trp, tryptophan; Tyr, tyrosine; Cer, ceramide; PI, 
phosphatidylinositol.rigorously established to have a beneficial effect on 
human health or in the treatment of disease. Biosynthetic 
pathways control the production and endogenous func-
tions of different glycan structures. The structural diver-
sity of the mammalian glycome is produced predomi-
nantly in the secretory pathway of the cell. Moreover, it is 
within the Golgi apparatus that glycans become increas-
ingly oligomeric and branched as they transit through 
this latter portion of the secretory system bound mostly 
for the cell surface and extracellular compartments.
Glycosylation produces different types of glycans 
(or glycoconjugates) that are typically attached to cel-
lular proteins and lipids (Figure 1). Protein glycosylation 
encompasses N-glycans, O-glycans, and glycosami-
noglycans (frequently termed proteoglycans). N-gly-
cans are linked to asparagine residues of proteins, spe-
cifically a subset residing in the Asn-X-Ser/Thr motif, 
whereas O-glycans are attached to a subset of serines 
and threonines (Schachter, 2000; Yan and Lennarz, 
2005). Although glycosaminoglycans are also linked to 
serine and threonine, they are linear, are produced by 
different biosynthetic pathways, and are often highly sul-
fated (Esko and Selleck, 2002). Lipid glycosylation in the 
secretory pathway is also a prevalent modification and 
creates glycolipids (glycosphingolipids) that include the 
sialic acid-bearing gangliosides (Maccioni et al., 2002). 
Glycosylphosphatidylinositol (GPI)-linked proteins share 
a common membrane-bound glycolipid linkage struc-
ture that is attached to various proteins (Kinoshita et al., 
1997). Hyaluronan is a unique glycan type unattached 
to either proteins or lipids that is secreted into extracel-
lular compartments (Weigel et al., 1997). Less common 
types of protein glycosylation also occur, for example, 856 Cell 126, September 8, 2006 ©2006 Elsevier Inc.on lysine, tryptophan, and tyrosine residues of specific 
proteins, such as glycogen, which was the first identi-
fied glycoprotein. In addition, although technically not 
glycosylation, acetyltransferase and sulfotransferase 
enzymes residing in the secretory pathway frequently 
attach acetyl and sulfate groups to selected saccha-
rides residing on some oligosaccharide chains and can 
thereby modulate glycan structure and function (Klein 
and Roussel, 1998; Fukuda et al., 2001).
Some forms of glycosylation occur outside of the 
secretory pathway. Among most eukaryotic organisms, 
N-acetylglucosamine has been found linked to serine 
and threonine residues (O-GlcNAc) on many cytoplas-
mic and nuclear proteins (Hart, 1997). Similar to protein 
phosphorylation, GlcNAcylation is an enzymatic modi-
fication that typically has a shorter half-life than that of 
the attached proteins. This reflects the presence of a 
regulated cytoplasmic N-acetylglucosaminidase, which 
removes O-GlcNAc, leaving the serine or threonine resi-
due subsequently available for another round of GlcNAc-
ylation or sometimes phosphorylation. O-GlcNAc is a 
highly regulated posttranslational modification required 
for the viability of many mammalian cell types perhaps 
by acting as a nutrient sensor, preventing protein phos-
phorylation, or regulating protein turnover (Zhang et al., 
2003; O’Donnell et al., 2004; Zachara and Hart, 2004).
It is useful to distinguish secretory and cytoplasmic 
glycosylation from glucuronidation, the latter being an 
enzymatic process linking a single glucuronic acid to 
bile salts and xenobiotics (molecules that are foreign to 
cells) (Tukey and Strassburg, 2000). In contrast to glyco-
sylation, glycation refers to the covalent linkage of sac-
charides such as glucose to proteins by a nonenzymatic 
Figure 2. Cellular Regulation of Glycan 
Expression
Representation of multiple mechanisms that 
alter cellular glycosyltransferase or glycosi-
dase expression, strucure, and activity, which 
can thereby regulate the formation of glycans. 
These include (1) control of glycosyltransfer-
ase and glycosidase gene transcription, (2) 
synthesis and transport of nucleotide sugar 
donors to the ER and Golgi (sugar transport-
ers not depicted), (3) modulation of enzymatic 
structure through phosphorylation, (4) relative 
amounts of enzymes that compete for identi-
cal substrates, (5) intracellular enzyme traf-
ficking and altered access to substrates, (6) 
proteolysis within the lumen of the Golgi re-
sulting in secretion of catalytic domains, and 
(7) glycan turnover at the cell surface by en-
docytosis coincident with expression of dif-
ferent glycans from altered glycan synthesis. 
Effects of glycosyltransferase and glycosi-
dase cytoplasmic tail phosphorylation (3) and 
intraluminal proteolysis (6) on cellular glyco-
sylation remain to be established. Structural 
information on the composition of glycans 
can be obtained from Figure 1.and irreversible process that is elevated in various dis-
eases and may be a factor in the pathology of aging (Suji 
and Sivakami, 2004).
Regulation of Mammalian Glycosylation
Glycans are constructed in an ordered sequential man-
ner involving the distinct substrate specificities of glyco-
syltransferase and glycosidase enzymes. Glycosyltrans-
ferases synthesize glycan chains, whereas glycosidases 
hydrolyze specific glycan linkages. Although glycosyl-
transferases are the anabolic component of glycosyl-
ation, both types of enzymes collaborate to determine 
the structural outcome in pathways of glycan biosyn-
thesis. Such properties are exemplified by mammalian 
N-glycan biosynthesis (Kornfeld and Kornfeld, 1985). 
Similarly, the biosynthetic pathways for the produc-
tion of O-glycans, glycosaminoglycans, and glycolipids 
are comprised of single enzymatic steps that typically 
rely upon glycan structures produced by the previous 
enzyme to produce the substrate for the next (Schachter, 
2000; Maccioni et al., 2002; Esko and Selleck, 2002). 
Although a one enzyme/one saccharide linkage para-
digm applies to almost all biosynthetic steps, numerous 
glycosyltransferase isozymes exist, and these underlie 
the breadth of glycan participation among different cell 
types and physiological processes.
Glycosylation in the secretory pathway is a dynamic 
process with multiple mechanisms that alter glycos-
yltransferase and glycosidase expression and struc-
ture, as well as their accessibility to substrates. Thus, 
in concert with protein and lipid turnover, glycosylation 
can regulate glycan variation (Figure 2). Structural varia-
tions in the glycan repertoire at the cell surface produce 
numerous biomarkers, some of which correlate with dif-ferentiation, cell activation, and disease. For example, 
elevated levels of truncated O-glycans (known as T anti-
gens) can be prognostic for reduced survival of patients 
with certain types of cancer (Hakomori, 2002; Kobata 
and Amano, 2005).
Gene transcription has a major impact on glycan 
formation, which is reflected by the cell-type-specific 
and developmentally modulated RNA expression pro-
files observed among many glycosyltransferases and 
glycosidases. Microarray approaches that detect the 
transcript levels of enzymes involved in constructing 
the glycome will be increasingly useful in categorizing 
these changes and perhaps provide predictive informa-
tion on cellular glycan expression patterns (Comelli et 
al., 2006). Transcriptional regulation of RNA abundance 
occurs among glycosyltransferase genes encoding, 
for example, GlcNAcT-V and Core 2 GlcNAcT-I. The 
GlcNAcT-V gene promoter bears Ets transcription factor 
binding elements that induce transcription in response 
to signals emanating from several key regulators of cell 
proliferation, including the Her-2/Neu oncogene. Core 
2 GlcNAcT-I is induced by the T-bet transcription fac-
tor in T helper type 1 lymphocytes (Chen et al., 1998; 
Underhill et al., 2005). Although multiple transcriptional 
networks regulate glycosyltransferase and glycosidase 
gene expression, the effect of this regulation on cellular 
processes remains largely unknown.
The expression of mammalian glycans is regulated at 
both a posttranscriptional and posttranslational level. 
Currently, this does not appear to involve modulation of 
enzymatic activity, as glycosyltransferases and glycosi-
dases are constitutively active. Nevertheless, some must 
be properly glycosylated themselves to be active, which 
suggests a possible mechanism of catalytic regulation Cell 126, September 8, 2006 ©2006 Elsevier Inc. 857
in vivo. Mechanisms altering the intracellular location of 
glycosyltransferases and glycosidases can be an effec-
tive means of regulating glycan formation by controlling 
access to acceptor substrates. Major changes in the gly-
come are induced by the loss of some chaperones and 
multiprotein complexes that alter glycosyltransferase 
trafficking between the endoplasmic reticulum and Golgi 
(Wu et al., 2004; Ju and Cummings, 2005; Foulquier et 
al., 2006). A potential means by which glycosyltrans-
ferases and glycosidases may be regulated is through 
phosphorylation of their cytoplasmic tails, which might 
modulate intermolecular interactions leading to differen-
tial substrate access and intracellular trafficking. There 
is also evidence of competition among glycosyltrans-
ferases in vivo for substrates in the secretory pathway, 
which can modify glycan formation. Some glycosyl-
transferases that generate different saccharide linkages 
have distinct specificities for nucleotide sugar donors 
but the same acceptor substrate specificity; whereas 
others bear identical donor specificity but act on dif-
ferent acceptor substrates. Glycosyltransferases of the 
former type can be mutually exclusive in the assembly 
line of glycan formation; whichever enzyme modifies the 
substrate first can thereby redirect the synthetic path-
way and alter the structural outcome. This was observed 
by the in vivo blockade of Core 2 GlcNAcT function due 
to endogenous expression of ST3Gal-I in T cells. Both 
glycosyltransferases can act on the same acceptor sub-
strate, and loss of ST3Gal-I elevated Core 2 O-glycan 
synthesis without a change in Core 2 GlcNAcT enzyme 
activity (Priatel et al., 2000).
Disengagement of glycosyltransferases and glyco-
sidases from their membrane-anchored locations can 
occur by proteolysis and would be expected to abolish 
their activities in glycan formation, although evidence of 
this potential form of glycan regulation currently awaits 
further experimentation. The enzymes of mammalian 
glycosylation are predominantly type 2 transmembrane 
glycoproteins that contain a luminal catalytic domain 
linked to a luminal membrane-proximal “stem” domain. 
Cleavage by secretory proteases within the stem 
domain results in secretion of a catalytic domain frag-
ment. This fragment can be found in most body fluids 
and can be induced, for example, in response to inflam-
mation (McCaffrey and Jamieson, 1993). The purpose of 
this proteolysis is unknown, and the range of enzymes 
affected is unclear. Although such glycosyltransferase 
fragments retain enzymatic activity, and hence their abil-
ity to bind to available acceptor substrates, they are not 
likely to be catalyzing glycan formation among extracel-
lular compartments, as the concentration of nucleotide 
sugar donors outside of the cell’s secretory pathway is 
far below enzyme substrate binding affinities.
The hydrolysis of glycans on mammalian glycopro-
teins and glycolipids is associated with their degradation 
in lysosomes. However, endogenous mechanisms that 
cleave glycans at the cell surface may exist. Hydrolysis 
of mammalian cell-surface glycans is in fact a feature of 858 Cell 126, September 8, 2006 ©2006 Elsevier Inc.some pathogen infection strategies such as sialic acid 
binding and cleavage by influenza virus (Gagneux and 
Varki, 1999; also see the Minireview by L. Comstock and 
D. Kasper, page 847 of this issue). Proteolysis and traf-
ficking to the cell surface would place mammalian glyco-
sidase enzymes in the region of the cell-surface glyco-
calyx, where some glycans might be hydrolyzed. At least 
one mammalian glycosidase that cleaves sialic acids 
from glycans is a transmembrane protein that reaches 
the plasma membrane (Wang et al., 2004). Although 
examples of cell-surface glycoprotein alterations consis-
tent with removal of specific glycan linkages have been 
described—such as the highly reproducible reduction in 
some sialic acid linkages following immune activation 
of mammalian lymphocytes—this may be explained by 
endocytosis and turnover in which newly synthesized 
glycoproteins bear different glycans due to modulation 
of glycosyltransferase or glycosidase function.
The biosynthesis and availability of nucleotide sugar 
donor substrates can exert broad control over mam-
malian glycan formation. Blockade of donor biosyn-
thesis or functional loss of donor-specific transporters 
normally residing the endoplasmic reticulum and Golgi 
membranes can abolish cellular glycans that contain, 
for example, fucose or sialic acid linkages (Lubke et 
al., 2001; Smith et al., 2002; Schwarzkopf et al., 2002). 
In contrast, glucosamine supplementation to the hex-
osamine biosynthetic pathway can elevate synthesis 
of some donor substrates and increase production of 
various glycans in mammalian cells (Zachara and Hart, 
2004; Lau et al., 2005). Precisely how this occurs may 
reflect multiple factors including increased catalysis and 
changes in gene expression. The impact of such aug-
mented glycosylation upon mammalian physiology is 
not yet known, although this matter is worthy of careful 
investigation. With a number of regulatory mechanisms 
available, several and perhaps all of those discussed 
above are involved in modulating mammalian glycan 
expression.
Determinants of Mammalian Glycan Function
Few biological roles for mammalian glycosylation had 
been established even a decade ago. The rapid pace of 
discovery since then reflects the application of genetic 
tools and approaches to expand upon the existing foun-
dation of enzymatic, biochemical, and structural knowl-
edge. Glycosylation, like phosphorylation, produces 
numerous structural modifications, each of which may 
be capable of signaling. Likewise, absence of a single 
kinase or glycosyltransferase affects the modification 
of multiple proteins and lipids. In studies of phosphory-
lation, this is commonly interpreted as disruption of a 
signal transduction cascade. In glycosylation, the speci-
ficity of most glycosyltransferases and glycosidases for 
substrates is defined by glycan structure instead of pro-
tein and lipid determinants. Therefore, single enzymes 
can glycosylate multiple, seemingly unrelated, proteins 
and lipids. How then does glycan formation achieve a 
high level of specificity in cellular function? The answer 
may come from combining knowledge of glycan syn-
thesis and regulation with the phenotypes observed in 
intact organisms bearing defects in glycan formation.
Cultured cells bearing various enzymatic defects in 
the pathways of glycosylation typically lack significant 
phenotypes, yet a high degree of evolutionary conser-
vation is typical among mammalian glycosyltransferase 
and glycosidase orthologs (Amado et al., 1999; Kikuchi 
and Narimatsu, 2006). Glycosylation in the secretory 
pathway positions most glycans at the cell surface and 
extracellular compartments where cell-cell communi-
cation is occurring among various cell types in intact 
organisms. Such intercellular physiology is not typi-
cally replicated in immortalized cell-line monoculture 
systems. GlcNAcT-1 glycosyltransferase deficiency, for 
example, which was well tolerated among cell lines in 
vitro, resulted in severe embryonic defects with situs 
inversus of heart loop formation, aberrant vasculariza-
tion, and other morphogenic abnormalities in mouse 
ontogeny, indicating the need to use intact organisms 
to study mammalian glycosylation (Ioffe and Stanley, 
1994; Metzler et al., 1994). Since these findings, doz-
ens of mouse lines have been created bearing germline 
defects in specific steps of the various glycosylation 
pathways. Remarkably, most of these inherited glycan 
deficiencies result in discrete phenotypes that reflect 
the dysfunction of specific cell types and diverse bio-
logical systems (Lowe and Marth, 2003).
Glycans possess distinct structural elements that 
govern interactions with other molecules. Glycans can 
promote or inhibit intra- and intermolecular binding that 
includes both homotypic and heterotypic interactions 
(Figure 3). Furthermore, mammalian glycans can be so 
substantial in size and frequency of attachment that they 
contribute the majority of mass and charge comprising 
some glycoproteins and glycolipids. For example, the 
neural cell adhesion molecule NCAM has a uniquely 
large negatively charged and devel-
opmentally regulated glycan structure 
known as polysialic acid that inhib-
its homotypic NCAM protein-protein 
binding (Hoffman and Edelman, 1983). 
It has been shown that polysialic acid 
on NCAM must be regulated in mouse 
development for selective axonal traf-
ficking, emotional and cognitive memory, and brain mor-
phogenesis. Comparative studies of phenotypes have 
indicated that the polysialic acid glycan component is 
required for the proper execution of almost all of the 
physiological functions attributed to NCAM (Angata et 
al., 2004; Weinhold et al., 2006). Furthermore, mucins 
represent an example of a class of glycoproteins bear-
ing a large number of O-glycan linkages that can induce 
steric effects that extend the conformation of a peptide 
backbone and may thereby serve to prominently dis-
play a large number of glycan decoys for pathogen lec-
tin receptors in human resistance to oral and mucosal 
infection (Tabak, 1995).
Glycosylation determines ligand abundance for 
endogenous mammalian lectins. Lectins are glycan 
binding proteins that are typically highly selective for 
specific glycan structures and have therefore been 
extremely useful in studying glycan variation (Goldstein, 
2002; Sharon and Lis, 2004). An expanding number of 
mammalian lectins have been identified and are classi-
fied by sequence motifs such as those that define the 
C-type lectins, S-type lectins, P-type lectins, and the 
Siglecs (Crocker and Varki, 2001; Drickamer and Taylor, 
2003). It is likely that other lectin domains exist, as some 
proteins with apparent lectin activity do not contain 
canonical glycan binding motifs. Both lectin binding by 
chaperones and steric effects of glycans contribute sub-
stantially to protein folding prior to trafficking to the Golgi 
and beyond by reducing protein aggregation and retain-
ing nascent unfolded glycoproteins in the endoplasmic 
reticulum (Parodi, 2000; Helenius and Aebi, 2004).
The interaction between glycans and lectins typically 
occurs with lower affinity than protein-protein interac-
tions but with significant avidity given that most lectins 
can bind multiple glycan moieties and do so with high 
specificity. Glycans in the region of the glycocalyx can 
reach millimolar concentrations, and, when bound by 
endogenous lectin receptors, such interactions can be 
Figure 3. Glycans Modulate Molecular 
Interactions
Lectin binding and steric mechanisms involving 
glycan structures in the control of protein-protein 
interactions are depicted. Glycans can modulate 
intramolecular and intermolecular binding com-
prising both homotypic and heterotypic interac-
tions. The participation of protein conformation 
and protein-protein binding in concert with lectin 
binding is also denoted. Most of these interac-
tions depicted reflect various degrees of experi-
mental support among the current literature.Cell 126, September 8, 2006 ©2006 Elsevier Inc. 859
difficult to disrupt by lower concentrations of glycan 
ligand mimetics. Moreover, some mammalian lectins at 
the cell surface can appear fully occupied, or “masked,” 
by binding to endogenous glycan ligands (Crocker and 
Varki, 2001). Yet even in the presence of glycan ligands 
residing on numerous glycoproteins, recent studies 
have observed that endogenous lectin binding in situ 
on primary cell surfaces can be surprisingly selective 
for ligands presented by distinct glycoproteins, implying 
that protein sequence and conformation contribute to 
mammalian lectin binding selectivity (Collins et al., 2004; 
Han et al., 2005; Ohtsubo et al., 2005). This may be fur-
ther understood when glycoprotein ligands are visual-
ized at the atomic level. Technical limitations at present, 
however, restrict acquisition of three-dimensional struc-
tures of glycoproteins to those produced by expression 
systems that lack most mammalian glycans.
Regulation of Cellular Mechanisms by Glycans
By binding to lectins and sterically modulating molecu-
lar interactions, mammalian glycans participate in mul-
tiple cellular mechanisms that contribute to health and 
disease. These basic structural paradigms have been 
found to regulate protein folding, cell adhesion, molec-
ular trafficking and clearance, receptor activation, sig-
nal transduction, and endocytosis (Figure 4). Numer-
ous functions of mammalian glycans are now evident, 
and some may have arisen early in the evolution of mul-
ticellular and vertebrate organisms.
Cell Adhesion
Lectin binding can evoke cell-cell adhesion and aggrega-
tion among primitive eukaryotic multicellular organisms 
(such as sponges) and may have contributed to cell-
based kin recognition in the evolution 
of the earliest metazoans. Mammalian 
lectin involvement in cell-cell adhesion 
is best characterized for the selectins 
and their glycan ligands that include a 
key fucose linkage on the sialyl-Lewis 
X oligosaccharide (Lowe, 2003). This 
cell adhesion system is highly regu-
lated on specific cell surfaces including 
the endothelium of the vasculature and 
on most leukocytes, thereby contribut-
ing to leukocyte trafficking responses 
that are essential in immune-system 
homeostasis, hematopoiesis, and inflammation (Rosen, 
2004). Glycosylation can also modulate cell-cell adhe-
sion in early mammalian embryos, and loss of some 
glycans disrupts fertilization, by mechanisms that are 
less well resolved. However, these results indicate 
that other lectin-ligand binding interactions governing 
cell-cell adhesion likely exist (Surani, 1979; Akama et 
al., 2002; Shur et al., 2004). When cellular portfolios 
of glycosyltransferases and glycosidases are altered 
in embryogenesis and disease and act upon a differ-
ent assemblage of protein and lipid substrates, the 
production of rare glycoprotein and glycolipid epitopes 
can occur. Such unusual glycan-dependent epitopes 
often define today’s known oncofetal and stem cell 
biomarkers that reflect the various binding specificities 
of different monoclonal antibodies. Glycan biomarkers 
of biologic and pathogenic processes further include 
selectin-dependent cell adhesion that is associated in 
some contexts with tumorigenic activity (Varki and Varki 
2001; Chen et al., 2005).
Self/Nonself Recognition
The ability of mammalian lectins to recognize glycans 
from divergent organisms such as bacteria, yeast, and 
invertebrates underlies a mechanism of self/nonself rec-
ognition. This is exemplified by Toll-like receptor activa-
tion of the innate immune system from binding to bacte-
rial glycan ligands (Barton and Medzhitov, 2003). Many 
lectins are expressed on cells of the mammalian innate 
immune system, and several bind to glycans specifically 
expressed among phylogenetically older organisms. 
Perhaps defects in mammalian glycosylation can influ-
ence self/nonself recognition and in some contexts lead 
to autoimmune disease. In this regard, the absence in 
Figure 4. Cellular Mechanisms of Glycan 
Function
Glycans produced in the secretory pathway 
participate in multiple mechanisms of cellular 
regulation. The influence of glycans on protein-
protein interactions encompasses a number of 
cellular functions that span from nascent protein 
folding and intracellular trafficking to roles in 
extracellular compartments where cell-cell com-
munication is modulated by adhesion, molecular 
and cellular homeostasis, receptor activation 
and signal transduction, and endocytosis.860 Cell 126, September 8, 2006 ©2006 Elsevier Inc.
regulates the activation of various cell-surface growth-mice of α-mannosidase II, a glycosidase necessary in 
nonimmune cells for the normal synthesis of mamma-
lian N-glycan structures bearing multimeric branching 
patterns, was found to induce a syndrome diagnostic of 
systemic lupus erythematosus (Chui et al., 2001). There-
fore, in this model of autoimmune disease, pathogenesis 
may reflect endogenous epitope (N-glycan) modification 
(Wakeland et al., 2001). Innate immune-system recogni-
tion of endogenous glycans has been observed follow-
ing the enzymatic breakdown of the glycan hyaluronan 
into smaller fragments upon dermal injury, which then 
activate the Tlr4 Toll-like receptor (Taylor et al., 2004). 
Normal mammalian glycan structures can also func-
tion as self-antigens in facilitating the development of 
immune cell types and their responses to infection, such 
as in the establishment of NKT cells by endogenous gly-
colipid ligands for CD1d (Zhou et al., 2004). Moreover, 
a significant proportion of endogenous mammalian 
glycans may participate in binding to major histocom-
patibility complexes and glycopeptide recognition by T 
cell receptors (Carbone and Gleeson, 1997). This may 
reflect a steric mechanism of glycan function in peptide 
processing and loading onto major histocompatibility 
complexes, in contrast with the role of glycans in endog-
enous lectin receptor binding.
Molecular Trafficking and Clearance
Glycan recognition by vertebrate lectins was discovered 
in studies of glycoprotein clearance from vascular circu-
lation and retains commercial relevance in therapeutic 
glycoprotein engineering. Glycoprotein turnover by the 
liver can be dramatically accelerated by lectins known 
as asialoglycoprotein receptors, which bind to and 
internalize glycoproteins lacking or bearing insufficient 
sialic acid linkages (Ashwell and Harford, 1982). Yet 
the purpose of these receptors remains puzzling, and 
recent findings suggest that some sialic acid-bearing 
glycans can also be recognized by these lectins (Park et 
al., 2005). Given that serum glycoprotein levels appear 
normal in mice lacking the hepatic asialoglycoprotein 
receptor, endogenous ligands within normal mammals 
have not been identified yet (Ishibashi et al., 1994). 
Moreover, multiple asialoglycoprotein receptors exist 
among endothelial cells, hepatocytes, dendritic cells, 
macrophages, and Kupffer cells whose functions are 
currently unknown. Possible roles of asialoglycoprotein 
receptors include the modulation of acute inflammation 
responses and the phagocytosis of some pathogens 
bearing particular glycan linkages. More recently, both 
platelets and the von Willebrand factor (vWF) glycopro-
tein were identified as endogenous ligands for mam-
malian asialoglycoprotein receptors in the presence 
of a defect in ST3Gal-IV sialyltransferase expression, 
which resulted in decreased thrombosis in the mouse 
(Ellies et al., 2002). Unexpectedly, deficiency of a sepa-
rate sialyltransferase, ST6Gal-I, failed to alter vWF and 
platelet homeostasis, which implies that the activities of 
specific glycosyltransferases and glycoproteins underlie 
the specificity in this lectin system. The development of glycan array technologies can facilitate both broad and 
quantitative characterization of glycan binding specifici-
ties among isolated lectins and thus may aid in identi-
fying glycoprotein ligands that dictate the biological 
roles of these and other endogenous mammalian lectins 
(Bochner et al., 2005).
Genes encoding some lectins include multiple exons 
encoding different extracellular domains and motifs 
with distinct glycan binding specificities. The Man/Gal-
NAc-4-SO4 receptor of macrophages and endothelial 
cells may bind mannose linkages or sulfated GalNAc 
residues in this way, the latter being restricted to a 
small number of glycoprotein hormones such as lutro-
pin that are released in a pulsatile manner from the 
pituitary gland in the brain. Sulfated glycoprotein hor-
mone clearance by the Man/GalNAc-4-SO4 receptor 
thereby modulates hormone bioactivity levels in vivo, 
which control female fecundity involving ovulation and 
embryo implantation (Mi et al., 2002). The role of man-
nose recognition by this lectin is unclear, although its 
absence from mice also induces serum glycoproteins 
typical of inflammation (Lee et al., 2002). Not all bio-
logical effects involving glycans influence cell adhesion 
or molecular trafficking and clearance from the extra-
cellular milieu. In contrast, some glycans (particularly 
glycosaminoglycans) serve to sustain reservoirs of 
extracellular growth factors and cytokines for use in 
modifying receptor binding and activation.
Receptor Activation
Glycosylation modulates interactions of receptors and 
ligands with themselves, coregulatory molecules, and 
distinct membrane domains of intact cells, thereby 
altering signal transduction. For example, fibroblast 
growth-factor receptors bind to specific heparan sul-
fate glycosaminoglycans on some proteoglycans, and 
this interaction facilitates the copresentation of ligand 
monomers to achieve receptor dimerization and activa-
tion (Ornitz et al., 1992). Glycosaminoglycans exist as 
multiple subtypes that include not only heparan sulfate 
but also chondroitin sulfate, dermatan sulfate, and kera-
tin sulfate and are major constituents of the extracellu-
lar matrix. Alteration of the sulfation pattern on glycos-
aminoglycans by endogenous sulfatases provides an 
example of a contrasting receptor activation mecha-
nism. Here, selective desulfation unmasks Wnt binding 
domains, thus facilitating ligand presentation of Wnt to 
its receptor Frizzled (Ai et al., 2003). Multiple receptor 
systems appear to employ glycosaminoglycans on pro-
teoglycans to modulate receptor activation in regulat-
ing morphogenesis and organogenesis signaling during 
early ontogeny. Moreover, the ability of glycosaminogly-
cans to bind to receptor ligands and retard their diffu-
sion has emerged as a mechanism of establishing mor-
phogen gradients that specify the differentiation of cell 
types during embryogenesis (Belenkaya et al., 2004).
Perhaps all types of mammalian glycans are involved 
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factor receptors by mechanisms that also modulate 
ligand binding and receptor dimerization (Miljan and 
Bremer, 2002). More unusual and rare glycan linkages 
are also regulatory. For example, Notch receptor traf-
ficking, ligand binding, and activation is regulated by an 
O-fucose linkage produced in the endoplasmic reticu-
lum and elaborated further in the Golgi by the Fringe gly-
cosyltransferase (Haines and Irvine, 2003). In contrast, 
it can be difficult to identify the molecular constituents 
involved when a genetic defect in glycan formation alters 
the glycosylation of multiple proteins and/or lipids. This 
provides the impetus for developing glycoproteomics 
and glycolipidomics technologies that can extend the 
identification of the cellular proteome and lipidome to 
more precisely characterize biologically relevant mol-
ecules (Dell and Morris, 2001).
The phenotypes associated with glycan linkage 
defects have often revealed the roles of glycans in 
important cellular processes that were not previously 
thought to be regulated by protein glycosylation. Loss 
of the GlcNAcT-V glycosyltransferase, for example, was 
found to induce coclustering of T cell receptors at the 
cell surface, reducing the threshold for immune activa-
tion and causing autoimmune disease (Demetriou et al., 
2001). This was attributed to the loss of T cell receptor 
binding to galectin-3, one of a family of lectins implicated 
in maintaining a spatially confined arrangement of cell-
surface glycoproteins (Morris et al., 2004). In addition, 
receptors for EGF and TGF-β on epithelial cells, the IgM B 
cell antigen receptor (BCR), and the glucose transporter 
2 glycoprotein on pancreatic β cells are all profoundly 
modulated by mammalian glycosylation, indicating that 
different glycans produced in the Golgi maintain these 
receptors at the cell surface by reducing their rates of 
endocytosis (Partridge et al., 2004; Ohtsubo et al., 2005; 
Collins et al., 2006; Grewal et al., 2006).
Endocytosis
Endocytosis plays a critical role in cell biology by pro-
viding access to material from extracellular compart-
ments, directing molecular cargo to distinct organelles, 
terminating or modifying signals emanating from the cell 
surface, and inducing the turnover of cell-surface mol-
ecules. Recent studies have found that mammalian gly-
cans produced in the Golgi modulate the endocytosis of 
cell-surface glycoproteins and thereby control receptor 
expression and hence thresholds for cell signaling. The 
glycan linkage produced by GlcNAcT-V, for example, 
retards EGF and TGF-β receptor endocytosis, thereby 
altering receptor activation and signaling among epi-
thelial carcinoma cells (Partridge et al., 2004). Different 
cell types appear to use distinct glycans to alter rates of 
endocytosis, and selectivity can further exist among the 
cell-surface glycoproteins of a given cell type. Pancre-
atic β cells, but not hepatocytes, for example, appear 
to use a lectin mechanism to decrease the rate of endo-
cytosis involving glucose transporter 2—but not other 
similarly glycosylated proteins—in preventing the onset 
of type 2 diabetes (Ohtsubo et al., 2005).862 Cell 126, September 8, 2006 ©2006 Elsevier Inc.Lectins and their ligands can modulate cell-surface 
receptor activation coincident with the regulation of 
receptor endocytosis. This is perhaps best character-
ized for CD22 (Siglec-2), a mammalian B cell-specific 
lectin that modulates BCR activation and thereby alters 
humoral immune responses. Like most Siglecs, CD22 
contains both an extracellular lectin domain that binds 
to specific sialic acid-bearing glycans and intracellular 
protein sequence motifs that can bind to intracellular 
signal transduction proteins and regulate phosphory-
lation. The cytoplasmic domain of CD22 plays a nega-
tive regulatory role by recruiting the Shp-1 phosphatase 
and thereby downmodulating immune signaling when 
CD22 is associated with the BCR (Tedder et al., 1997). 
Genetic deficiency of the ST6Gal-I glycosyltransferase 
in the mouse results in loss of CD22 Siglec ligands and 
diminishes BCR activation and signaling. This correlated 
with increased colocalization of BCRs with CD22, con-
stitutive Shp-1 recruitment to CD22, decreased protein 
phosphotyrosine levels, elevated BCR trafficking to 
clathrin microdomains, and enhanced endocytosis of 
BCRs (Collins, et al., 2006; Grewal et al., 2006). In mice 
deficient for both CD22 and ST6Gal-I, BCR signaling as 
well as microdomain association and endocytotic rate 
were restored to normal. Moreover, the reduced level 
of humoral immunity in mice with ST6Gal-I deficiency 
further prevented the development of autoimmune dis-
ease, unlike findings in their normal counterparts that 
bore lower levels of BCR-CD22 interactions. This lec-
tin-ligand system therefore modulates the threshold of 
B cell immune activation in a mechanism linked to BCR 
trafficking and endocytosis.
Diseases of Glycosylation
Endocytosis and trafficking to lysosomes are typically 
involved in degrading proteins and glycans. Defects in 
these catabolic steps include glycosidase deficiencies 
that form the bases for cellular storage disorders such 
as Gaucher’s, Niemann-Pick type C, Sandhoff’s, and 
Tay-Sachs diseases. A subset of these maladies can 
now be clinically treated using a small-molecule analog 
of a plant-derived organic compound that reduces glu-
cosyltransferase I activity. This compound represents 
the first drug marketed for human disease therapy that 
inhibits an endogenous mammalian glycosyltransferase 
as a mechanism of action (Butters et al., 2005). Remark-
ably, unlike protein kinase inhibitors that compete with 
the donor substrate ATP, glycosyltransferase inhibitors 
generally do not compete with nucleotide sugar donor 
substrates but are competitive with specific glycan 
acceptor substrates.
Defects in the anabolic process of glycan formation 
are more typically considered as human diseases of gly-
cosylation. I cell disease was the first to be identified and 
was shown to result from failure to produce the mannose 
6-phosphate modification on N-glycans in the Golgi. This 
modification acts as a signal that is necessary for traf-
ficking of hydrolases to the lysosome. Absence of this 
signal therefore also causes a storage disorder due to a 
deficiency in protein catabolism (Kornfeld and Sly, 1985). 
The genetic basis of I cell disease encompasses muta-
tions in the gene encoding the GlcNAc-phosphotrans-
ferase α/β subunit precursor (Kudo et al., 2006).
An increasing number of diseases of glycosylation 
are being discovered, especially in the pediatric clinic 
among children during the first few years of life. The con-
genital disorders of glycosylation (CDGs) refer to a large 
number of syndromes that include severe morphogenic 
and metabolic defects associated with general failure to 
thrive, most of which have been linked to distinct steps 
in glycan formation (Jaeken and Carchon, 2004). Those 
among the most prevalent grouping (CDG type 1a) are 
due to hypomorphic mutations in the PMM2 gene. Muta-
tions in this gene diminish synthesis of the dolichol-oli-
gosaccharide precursor, which is essential for initiation 
of N-glycosylation, and hence decrease the frequency 
of N-glycosylation. A small number of CDG subtypes 
reflect defects in the formation of nucleotide sugar 
donor substrates, and some can be treated by dietary 
intake of precursor saccharides, as exemplified by man-
nose ingestion, which reverses signs of CDG type 1b 
disease (Niehues et al., 1998). At present, at least 20 
separate genes and more than 100 allelic variants have 
been identified among the CDGs, many of which involve 
hypomorphic mutations that impact on glycosyltrans-
ferase and glycosidase enzyme activities, as well as 
genetic defects in synthesis and transport of nucleotide 
sugar donors (Aebi and Hennet, 2001; Freeze, 2006).
How many diseases of glycosylation exist in the human 
population, and what are their frequencies of occur-
rence? The answers are not yet known. Their detection 
is serendipitous due to infrequent clinical application of 
serum transferrin isoelectric focusing and other electro-
phoretic techniques to the analysis of specific glycopro-
teins. Although these are presently essential diagnostic 
tools, they are nevertheless unable to detect most gly-
can linkage defects. Thus, human glycosylation disor-
ders identified so far are primarily severe syndromes, 
many of which reflect the disruption of early steps in 
the pathways of glycan biosynthesis. In contrast, mouse 
models of defective glycosylation have been engineered 
to ablate both early and late biosynthetic steps. From 
these studies, it has become evident that the later the 
defect in glycan synthesis, the less likely it is that a single 
glycosyltransferase or glycosidase deficiency will cause 
a severe multisystemic disorder leading to dysmorphic 
features, failure to thrive, and lethality. The only interspe-
cies and biochemically comparable model documented 
at present is loss of GlcNAcT-II glycosyltransferase activ-
ity, which is the basis for the human CDG-IIa syndrome. 
Mice lacking GlcNAcT-II activity closely phenocopy 
human CDG-IIa disease signs, and strain-associated 
variations in disease severity were also observed (Wang 
et al., 2001). These findings suggest that animal models 
may be useful in studying the molecular and pathogenic 
bases for human diseases of glycosylation.Connections between glycans and human disease 
are now being made every year and have expanded to 
include mild as well as severe syndromes, with timing of 
onset that can span from early neonatal to adult life. The 
defects and symptoms further often imply cell- and tis-
sue-specific dysfunction. Human spondylocostal dysto-
sis has been recently linked to inactivation of the Lunatic 
Fringe glycosyltransferase corresponding to a defect in 
Notch signaling events essential in ontogenic patterning 
of the axial skeleton during embryogenesis (Sparrow et 
al., 2006). Humans lacking a functional ST3Gal-V glyco-
syltransferase, also known as GM3 synthase, develop an 
early neurological disorder termed infantile-onset symp-
tomatic epilepsy (Simpson et al., 2004). Mice lacking this 
enzyme at first appear unaffected, but later, some exhibit 
seizures as adults. Human hereditary multiple exostoses 
is an autosomal-dominant bone disease characterized 
by multiple cartilaginous tumors that occur throughout 
childhood and is caused by defects in the glycosyltrans-
ferases required for synthesis of the heparan sulfate gly-
cosaminoglycan (Duncan et al., 2001). Paroxysmal noc-
turnal hemoglobinuria usually occurs in adulthood and 
results from somatic mutation within the bone-marrow 
stem cell population resulting in a defect in GPI anchor 
synthesis (Bessler et al., 1994).
The participation of lectins and altered lectin binding 
would also be expected to contribute to pathogenesis 
among human diseases and reflect the physiologic func-
tions of glycosylation; however, few examples currently 
exist. This may imply that the roles of human lectins 
overlap in vivo, a possibility consistent with the minimal 
phenotypic consequences of most lectin deficiencies 
thus far induced and studied in the mouse. Alternatively, 
some lectin mutations in humans may have a more 
severe impact and disrupt embryogenesis, resulting in 
early lethality. However, some human muscular dystro-
phies are due to mutations in laminin as well as in glyco-
syltransferases operating in the pathway of O-mannose 
glycan formation on α-dystroglycan (McGowan and 
Marinkovich, 2000; Yoshida et al., 2001; Michele et al., 
2002). These defects occur coincident with disruption of 
α-dystroglycan attachment to laminin in what resembles 
a lectin binding mechanism.
Diseases that alter glycosylation have revealed new 
mechanisms regarding how glycan formation is regu-
lated. Inherited deficiencies in the conserved oligomeric 
Golgi (COG) complex members COG1 and COG7 in 
humans result in a severe childhood disease and peri-
natal death, respectively (Wu et al., 2004; Foulquier et 
al., 2006). Cells from these patients lack expression of 
many different glycans, which may contribute to the 
pathogenic basis of these syndromes. And the elusive 
cause of human Tn syndrome, an adult hematologic dis-
order, was recently identified as a genetic mutation in the 
COSMC gene encoding a protein with chaperone func-
tion required for β1-3 galactosyltransferase activity in O-
glycan biosynthesis (Ju and Cummings, 2005). Human 
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changes in glycosyltransferase and glycosidase activity. 
Endogenous sporadic or germline modifications of the 
primary structure of single proteins may also contribute. 
A recent analysis of glycoprotein mutations in the human 
disease database revealed a larger-than-random occur-
rence of amino acid changes in proteins that predict a 
gain-of-N-glycosylation, and those that were tested 
indeed acquired an N-glycan concurrent with glycopro-
tein dysfunction (Vogt et al., 2005).
Summary and Future Directions
Research on the function of mammalian glycosylation 
demonstrates that glycans are involved in multiple dis-
ciplines spanning ontogeny, immunology, neurobiol-
ogy, hematology, and metabolism and are linked to a 
number of genetic diseases. It is increasingly appar-
ent that biological networks exploit both glycosylation 
and phosphorylation by using cell-surface glycans to 
organize plasma membrane receptors and control the 
recruitment of intracellular signal transduction media-
tors. Hence, discoveries encompassing glycobiology 
will contribute to the knowledge needed to decipher the 
biological systems that comprise living organisms.
In some cases, glycans are the only source of variation 
between otherwise identical glycoproteins produced 
within the same cell, resulting in “microheterogeneity.” 
Such heterogeneity and its regulation may play a role 
in setting thresholds for molecular interactions that gov-
ern cellular responses. For example, certain glycoforms 
representing IgG microheterogeneity are increased in 
arthritis (Parekh et al., 1985). In addition, the anti-inflam-
matory property of IgG binding to Fc receptors is ele-
vated among the subset of total circulating IgGs that are 
sialylated, compared to the fraction of IgGs that have 
fewer or no sialic acid linkages (Kaneko et al., 2006). 
When glycosylation does occur, it may not always alter 
the folding, interactions, function, or fate of all proteins 
similarly modified. The function of an enzyme in modi-
fying many substrates does not dictate that all such 
modifications will manifest a biological purpose. This 
possibility is conspicuous in recent analyses of mouse 
models of glycan deficiencies in which the phenotype 
can be attributed to the modulation of single glycopro-
teins including CD22, glucose transporter 2, TGF-β1 
receptor, and von Willebrand factor (Ellies et al., 2002; 
Ohtsubo et al., 2005; Wang et al., 2005; Collins et al., 
2006; Grewal et al., 2006). Glycans attached to some 
proteins and lipids may be physiologically inert. Such 
nondeleterious glycosylation might impart subtle char-
acteristics to glycoproteins and glycolipids that become 
advantageous in response to new selective pressures 
applied by exogenous and pathogenic stimuli. In con-
trast, those endogenous glycans with essential physi-
ologic purpose would further maintain the sequence 
conservation evident among glycosyltransferase and 
glycosidase gene orthologs.
Although it is not possible to predict a cell’s glycan 
repertoire from analyses of genomic DNA sequences, 864 Cell 126, September 8, 2006 ©2006 Elsevier Inc.it is clear that the highly ordered, regulated, and con-
served pathways of glycan diversification have evolved 
to play specific biological roles, many of which are 
essential and have persisted throughout mammalian 
speciation. As biomedical connections to glycobiol-
ogy expand, therapeutic rationales for modulating and 
detecting glycan production and variation continue to 
emerge. Glycomics-based initiatives can assist by facili-
tating the development of techniques to produce com-
plex glycan structures, detect glycan interactions with 
other molecules, and enable glycan-based methodolo-
gies to modulate cell processes (Schweizer and Hinds-
gaul, 1999; Seeberger and Werz, 2005; Paulson et al., 
2006). Research encompassing glycobiology is highly 
interdisciplinary and increasingly successful in explain-
ing how extracellular signals originate and how cell-
cell communication is established among multicellular 
organisms. The amount of the genome invested in gly-
cosylation compared to what has been understood thus 
far implies that only a small fraction of glycan function 
has been decoded. The integration of glycobiology into 
mainstream education and research will further prepare 
the next generations of scientists to oversee the merg-
ing of now disparate biological disciplines into a cohe-
sive rendering of the molecular mechanisms that govern 
physiology and disease.
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